Ecnoglutide

What is Ecnoglutide?#

Ecnoglutide (XW003) is an investigational, long-acting, cAMP signaling-biased glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of type 2 diabetes and obesity. It is a 31-amino acid synthetic peptide analog of human GLP-1(7-37) with key structural modifications including an alanine-to-valine substitution at position 2 for DPP-4 resistance and a C18 fatty diacid chain conjugated at lysine-26 via a gamma-glutamic acid and dual mini-PEG linker for albumin binding and extended half-life.

The defining characteristic of ecnoglutide is its signaling bias. While conventional GLP-1 agonists like semaglutide activate both the cAMP pathway and beta-arrestin recruitment at the GLP-1 receptor, ecnoglutide was engineered to potently induce cAMP signaling (EC50 = 0.018 nM) while showing minimal receptor internalization (EC50 > 10,000 nM). This biased agonism profile may reduce tachyphylaxis and sustain receptor responsiveness during chronic treatment.

Sciwind Biosciences is developing ecnoglutide primarily in China, where it has completed Phase 3 trials in both type 2 diabetes (EECOH program) and obesity (SLIMMER trial). An oral formulation (XW004) is also in early development.

Mechanism of Action#

Ecnoglutide activates the GLP-1 receptor with a deliberate signaling bias toward the G protein-cAMP pathway.

Biased Agonism#

• cAMP signaling: Ecnoglutide potently activates the Gs protein-adenylyl cyclase-cAMP cascade at the GLP-1 receptor, stimulating insulin secretion and producing appetite-suppressing effects comparable to or exceeding those of unbiased GLP-1 agonists
• Minimal beta-arrestin recruitment: Unlike semaglutide and other conventional GLP-1 agonists, ecnoglutide shows negligible beta-arrestin recruitment, which is the pathway primarily responsible for GLP-1 receptor internalization and desensitization
• Sustained receptor signaling: By minimizing receptor internalization, ecnoglutide may maintain GLP-1 receptor surface expression and signaling capacity during chronic dosing, potentially improving long-term efficacy

Metabolic Effects#

• Glucose-dependent insulin secretion: Stimulates pancreatic beta-cells to release insulin when blood glucose is elevated
• Glucagon suppression: Reduces inappropriate glucagon release in the hyperglycemic state
• Appetite regulation: Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase satiety
• Gastric emptying delay: Slows gastric emptying to reduce postprandial glucose excursions

Pharmacokinetics#

Ecnoglutide has a half-life at steady state of 124-138 hours (approximately 5-6 days), supporting once-weekly subcutaneous dosing. The C18 diacid fatty acid chain enables non-covalent albumin binding, creating a circulating reservoir that protects the peptide from renal filtration and enzymatic degradation.

Research Overview#

Ecnoglutide has been evaluated across multiple clinical trials including Phase 1, Phase 2 (type 2 diabetes), and Phase 3 (both type 2 diabetes and obesity) studies. The most significant results include the Phase 3 SLIMMER obesity trial showing 15.4% mean weight loss at 48 weeks, and Phase 2/3 diabetes trials demonstrating HbA1c reductions up to 2.39%. Preclinical studies demonstrated superior weight loss compared to semaglutide in rodent models, which was attributed to the cAMP signaling bias maintaining sustained receptor activation.

All clinical trials to date have been conducted in Chinese populations, which is an important consideration for generalizability. Global development status and plans for regulatory submissions outside China have not been publicly disclosed.

Important Considerations#

• Investigational compound not approved by any regulatory agency
• All clinical data to date from Chinese populations only
• Safety profile appears consistent with the GLP-1 receptor agonist class (gastrointestinal adverse events most common)
• Long-term safety data beyond 48 weeks not yet available
• The biased agonism concept requires further validation in larger, longer-term studies

Key Research Findings#

Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog, published in Molecular Metabolism (Ren T et al., 2023; PMID: 37364710):

• The study showed phase 1 half life at steady state of 124-138 hours, supporting once weekly dosing

Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial, published in Nature Communications (Ji L et al., 2024; PMID: 39333121):

• The study showed HbA1c reductions of 1.81% , -1.90% , -2.39% vs -0.55%
• 71.9% of 1.2 mg group achieved HbA1c of 6.5% or less versus 9.1% placebo
• 33.3% of 1.2 mg group achieved body weight reduction of 5% or more versus 3.0% placebo

Efficacy and safety of ecnoglutide in adults with overweight or obesity: Phase 3 SLIMMER trial, published in The Lancet Diabetes and Endocrinology (Sciwind Biosciences investigators, 2025):

• The study demonstrated mean weight loss of 15.4% at 48 weeks with the highest dose
• The study demonstrated of participants achieved of 92.8% at least 5% weight loss at the highest dose

Related Reading#

• Ecnoglutide research studies and evidence
• Ecnoglutide dosing protocols
• Ecnoglutide side effects profile
• Semaglutide research guide
• Tirzepatide research guide